Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma

Cancer Treatment Communications

Volumn 2, Issue 2-3, 2014, Pages 34-47

  Tariman, Joseph D ^a   Doorenbos, Ardith ^b   Schepp, Karen G ^b   Becker, Pamela S ^c   Berry, Donna L ^d  

^a DEPAUL UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Decision making factors; Multiple myeloma; Older adults; Patient education; Treatment decision making

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMORBIDITY; CONTENT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LIFE EXPECTANCY; MALE; MYELOMA; PATIENT DECISION MAKING; PRIORITY JOURNAL; RISK FACTOR; SEMI STRUCTURED INTERVIEW; SOCIAL SUPPORT;

EID: 84925943639     PISSN: 22130896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrc.2014.08.003     Document Type: Article

References (56)

1. Renshaw C., Ketley N., Moller H., Davies E.A. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer 2010, 10:74.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA Cancer J. Clin. 2012, 62(1):10-29.
3. Waxman A.J., Mink P.J., Devesa S.S., Anderson W.F., Weiss B.M., Kristinsson N.Y. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010, 116(25):5501-5506.
4. Landgren O., Weiss B.M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009, 23(10):1691-1697.
5. Turesson I., Velez R., Kristinsson N.Y., Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin. Proc. 2010, 85(3):225-230.
6. Mehta J., Cavo M., Singhal S. How I treat elderly patients with myeloma. Blood 2010, 116(13):2215-2223.
7. Koreth J., Cutler C.S., Djulbegovic B., Behl R., Schlossman R.L., Munshi N.C. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol. Blood Marrow Transplant. 2007, 13(2):183-196.
8. Barlogie B., Kyle R.A., Anderson K.C., Greipp P.R., Lazarus H.M., Hurd D.D. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J. Clin. Oncol. 2006, 24(6):929-936.
9. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111(6):2962-2972.
10. Blade J., Rosinol L., Cibeira M.T., Rovira M., Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010, 115(18):3655-3663.
11. P.G. Richardson, J. Wolf, M. Liedtke, S. Lonial, T. Zimmerman, N. Raje, et al., Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-dose Treatment with SCT in MM Patients Up to Age 65 (DFCI 10-106). Info available at: , (accessed on 03-25-2014). http://clinicaltrials.gov/show/NCT01208662.
12. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. CD-ROM, 2011.
13. Berry D.L., Ellis W.J., Woods N.F., Schwein C., Mullen K.H., Yang C. Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol. Oncol. 2003, 21(2):93-100.
14. Zeliadt S.B., Moinpour C.M., Blough D.K., Penson D.F., Hall I.J., Smith J.L. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am. J. Manag. Care 2010, 16(5):e121-e130.
15. Schroen A.T., Brenin D.R. Breast cancer treatment beliefs and influences among surgeons in areas of scientific uncertainty. Am. J. Surg. 2010, 199(4):491-499.
16. Rogers S.O., Gray S.W., Landrum M.D., Klabunde C.N., Kahn K.L., Fletcher R.H. Variations in surgeon treatment recommendations for lobectomy in early-stage non-small-cell lung cancer by patient age and comorbidity. Ann. Surg. Oncol. 2010, 17(6):1581-1588.
17. Wasif N., Ye X., Giuliano A.E. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty. Ann. Surg. Oncol. 2009, 16(9):2442-2449.
18. Stewart A.K., Bergsagel P.L., Greipp P.R., Dispenzieri A., Gertz M.A., Hayman S.R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21(3):529-534.
19. Dispenzieri A., Rajkumar S.V., Gertz M.A., Fonseca R., Lacy M.Q., Bergsagel P.L. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted Therapy (mSMART): consensus statement. Mayo Clin. Proc. 2007, 82(3):323-341.
20. Palumbo A., Rajkumar S.V. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur. J. Haematol. 2010, 84(5):379-390.
21. Dingli D., Rajkumar S.V. How best to use new therapies in multiple myeloma. Blood Rev. 2010, 24(3):91-100.
22. Reece D.E. Recent trends in the management of newly diagnosed multiple myeloma. Curr. Opin. Hematol. 2009, 16(4):306-312.
23. Corso A., Varettoni M. The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation?. Curr. Stem Cell Res. Ther. 2007, 2(1):1-11.
24. Berry D.L., Ellis W.J., Russell K.J., Blasko J.C., Bush N., Blumenstein B. Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer. Clin. Genitourin. Cancer 2006, 5(3):219-226.
25. Bailey C., Corner J., Addington-Hall J., Kumar D., Nelson M., Haviland J. Treatment decisions in older patients with colorectal cancer: the role of age and multidimensional function. Eur. J. Cancer Care (Engl) 2003, 12(3):257-262.
26. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J. Natl. Cancer Inst. 2001, 93(11):850-857.
27. Hurria A., Leung D., Trainor K., Borgen P., Norton L., Hudis C. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit. Rev. Oncol. Hematol. 2003, 46(2):121-126.
28. Taylor W.C., Muss H.B. Adjuvant chemotherapy of breast cancer in the older patient. Oncology (Williston Park) 2010, 24(7):608-613.
29. Moore M., Gibbs P. Adjuvant chemotherapy use among older patients with stage III colon cancer. JAMA 2010, 303(23):2353-2354.
30. Wan-Chow-Wah D., Monette J., Monette M., Sourial N., Retornaz F., Batist G. Difficulties in decision making regarding chemotherapy for older cancer patients: a census of cancer physicians. Crit. Rev. Oncol. Hematol. 2011, 78(1):45-58.
31. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support. Oncol. 2003, 1(4 Suppl. 2):18-24.
32. Repetto L., Comandini D., Mammoliti S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit. Rev. Oncol. Hematol. 2001, 37(2):147-152.
33. Balducci L. ESH-SIOG international conference on haematological malignancies in the elderly. Expert Rev. Hematol. 2010, 3(6):675-677.
34. Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006, 20(2):135-143.
35. Martin V.C., Roberto K.A. Assessing the stability of values and health care preferences of older adults: a long-term comparison. J. Gerontol. Nurs. 2006, 32(11):23-33.
36. Sekeres M.A., Stone R.M., Zahrieh D., Neuberg D., Morrison V., De Angelo D.J. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18(4):809-816.
37. Hsieh H.F., Shannon S.E. Three approaches to qualitative content analysis. Qual. Health Res. 2005, 15(9):1277-1288.
38. Tariman J.D., Berry D.L., Cochrane B., Doorenbos A., Schepp K.G. Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review. Oncol. Nurs. Forum. 2012, 39(1):E70-E83.
39. QSR International Ltd., NVivo 8 Software. Retrieved from: , 2008. http://www.qsrinternational.com/FileResourceHandler.ashx/RelatedDocuments/DocumentFile/289/NVivo8-Getting-Started-Guide.pdf.
40. Hill C.E. A guide to conducting consensual qualitative research. Couns. Psychol. 1997, 25(4):517-572.
41. Krippendorff K. Reliability. Content Analysis: An Introduction to its Methodology 1980, 129-154. Sage Publications, Beverly Hills, CA.
42. Berry D.L., Maliski S.L., Ellis W.J. Qualitative research techniques. Clinical Research Methods for Surgeons. Human Press, Inc 2006, 297-310. D.F. Penson, J.T. Wei (Eds.).
43. Husain L.S., Collins K., Reed M., Wyld L. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective. Psychooncology 2008, 17(4):410-416.
44. Elit L., Charles C., Gold I., Gafni A., Farrell S., Tedford S. Women's perceptions about treatment decision making for ovarian cancer. Gynecol. Oncol. 2003, 88(2):89-95.
45. Kutner J.S., Vu K.O., Prindiville S.A., Byers T.E. Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract. 2000, 8(3):114-119.
46. Attal M., Harousseau J.L. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract. Res. Clin. Haematol. 2007, 20(4):747-759.
47. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 2003, 348(19):1875-1883.
48. Klepin H.D., Hurd D.D. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?. Bone Marrow Transplant 2006, 38(9):585-592.
49. Cohen H., Britten N. Who decides about prostate cancer treatment? A qualitative study. Fam. Pract. 2003, 20(6):724-729.
50. Shepherd H.L., Tattersall M.H., Butow P.N. Physician-identified factors affecting patient participation in reaching treatment decisions. J. Clin. Oncol. 2008, 26(10):1724-1731.
51. Blank T., Grave K., Sepucha K., Llewellyn-Thomas H. Understanding treatment decision making: contexts, commonalities, complexities, and challenges. Ann. Behav. Med. 2006, 32(3):211-217.
52. Kreling B., Figueiredo M.I., Sheppard V.L., Mandelblatt J.S. A qualitative study of factors affecting chemotherapy use in older women with breast cancer: barriers, promoters, and implications for intervention. Psychooncology 2006, 15(12):1065-1076.
53. Wong Y.N., Hamilton O., Egleston B., Salador K., Murphy C., Meropol N.J. Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist 2010, 15(6):566-576.
54. Ng A.K., Li S., Neuberg D., Silver B., Weeks J., Mauch P. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Ann. Oncol. 2004, 15(2):261-269.
55. Fowler F.J., McNaughton Collins M., Albertsen P.C., Zietman A., Elliott D.B., Barry M.J. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000, 283(24):3217-3222.
56. de Jong D., Aleman B.L., Taal B.G., Boot H. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann. Oncol. 1999, 10(3):275-280.